Ovid Therapeutics Inc. (OVID): Cash & Equivalents
$13.15M
As of 2025-12-31
$11.33M
As of 2026-06-30
-33.6%
3-year compound annual growth
-28.8%
5-year compound annual growth
-15.4%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.15M | -50.0% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $26.30M | -2.7% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $27.04M | -39.7% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $44.87M | -76.1% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $187.80M | +160.7% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $72.03M | +71.9% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $41.90M | +14.8% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $36.49M | -58.1% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $87.13M | +67.7% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $51.94M | -25.7% | 2018-03-29, Balance as of period end |
| 2015-12-31 | $69.94M | n/a | 2018-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $13.15M | -50.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $37.57M | +31.0% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $199.16M | +39.6% |
| Immunome Inc. (IMNM) | 2025-12-31 | $653.48M | +355.9% |
| Adagene Inc. (ADAG) | 2025-12-31 | $74.52M | -12.5% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $11.70M | +62.4% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $19.96M | -18.8% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $46.82M | +22.1% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $21.82M | -60.8% |
Compare OVID, WHWK, XENE, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗